Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Shares Outstanding for 10 consecutive years, with $265.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 18.05% to $265.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $265.4 million through Dec 2025, up 18.05% year-over-year, with the annual reading at $265.4 million for FY2025, 18.05% up from the prior year.
  • Shares Outstanding for Q4 2025 was $265.4 million at Akebia Therapeutics, roughly flat from $265.2 million in the prior quarter.
  • The five-year high for Shares Outstanding was $265.4 million in Q4 2025, with the low at $158.5 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $204.1 million, with a median of $188.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 1.34% in 2023, then increased 25.38% in 2025.
  • Over 5 years, Shares Outstanding stood at $177.0 million in 2021, then grew by 4.03% to $184.1 million in 2022, then rose by 5.67% to $194.6 million in 2023, then increased by 15.55% to $224.8 million in 2024, then increased by 18.05% to $265.4 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $265.4 million, $265.2 million, and $263.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.